Showing results (481-490 of 558) with videos related to

Sort By:
Pageof 56
Antiviral Therapy|March 8, 2006
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapyVijayan Balan, David R Nelson, Mark S Sulkowski, et al.
Genome Biology and Evolution|April 4, 2025
Chromosome-Level Assemblies of the Allohexaploid Genomes of Conyza sumatrensis and Conyza bonariensisAnthony Côrtes Gomes, Jacob Montgomery, André Lucas Simões Araujo, et al.
Scientific Reports|February 18, 2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infectionGary P Wang, Norah Terrault, Jacqueline D Reeves, et al.
Obesity Research & Clinical Practice|November 5, 2018
Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research ConsortiumDominick J Lemas, Michelle I Cardel, Stephanie L Filipp, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare DiseasesAdam Wanner, Stephen C Groft, J Russell Teagarden, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Leukemia|January 5, 2023
Molecular profiling of EBV associated diffuse large B-cell lymphomaFabian Frontzek, Annette M Staiger, Ramona Wullenkord, et al.
Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.
Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.
The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.
Pageof 56